

Special Issue

Advances in Autologous PRP Therapy

Message from the Guest Editor

Autologous PRP therapies have been used for more than 30 years, resulting in considerable interest in the field of regenerative medicine among diverse specialties. On one hand, PRP therapies are becoming suitable treatment options with clinical benefits and encouraging patient outcomes reported. On the other hand, production heterogeneity of PRP, the absence of systematic and standardized biological characterization, and an unclear mechanism of action have led to controversial results compared to other reference treatments and contributed to the fact that this therapy is struggling to be recognized as effective by the learned societies and still not covered by insurance companies.

This Special Issue of *Bioengineering*, will focus on recent advances in autologous PRP therapy research for therapeutic purposes, with no limit regarding the specialties using PRP. The research work submitted may be in vitro or in vivo experiments with a special interest for papers focusing on comprehension of PRP and platelets extracellular vesicles mechanism of action, as well as clinical studies, case series, or real-life studies in a context of therapeutic use.

Guest Editor

Dr. Jeremy Magalon

1. Cell Therapy Department, Marseille University Hospital, APHM, 13005 Marseille, France
2. Center of Cardiovascular Research & Nutrition, Pharmacy Faculty, Aix Marseille University, 13385 Marseille, France
3. Bioengineering Department, Pharmacy Faculty, Aix Marseille University, 13385 Marseille, France

Deadline for manuscript submissions

closed (31 August 2023)



Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



mdpi.com/si/137108

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)





Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.